PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments

Cancer Biology and Therapy

Volumn 9, Issue 10, 2010, Pages 762-775

  Tanjoni, Isabelle ^a   Walsh, Colin ^a   Uryu, Sean ^a   Tomar, Alok ^a   Nam, Ju Ock ^a   Mielgo, Ainhoa ^b   Lim, Ssang Taek ^a   Liang, Congxin ^c   Koenig, Marcel ^c   Sun, Connie ^d   Patel, Neela ^d   Kwok, Cheni ^d   McMahon, Gerald ^d   Stupack, Dwayne G ^b   Schlaepfer, David D ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d Poniard Pharmaceuticals Inc   (United States)

Author keywords

Apoptosis; Cell survival; FAK; Integrin; Tumor growth

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; DASATINIB; FOCAL ADHESION KINASE; FOCAL ADHESION KINASE INHIBITOR; PND 1186; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; AMINOPYRIDINE DERIVATIVE; CRK ASSOCIATED SUBSTRATE PROTEIN; TYROSINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASCITES TUMOR; BREAST CARCINOMA; CANCER INHIBITION; CARCINOMA CELL; CELL ADHESION; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; CYTOARCHITECTURE; DRUG MECHANISM; DRUG TOLERABILITY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; IC 50; MOUSE; NONHUMAN; OVARY CARCINOMA; PROTEIN EXPRESSION; SPHEROID CELL; SUBCUTANEOUS TISSUE TUMOR; ANIMAL MODEL; ENZYME ACTIVITY; TUMOR CELL; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; METABOLISM; MULTICELLULAR SPHEROID; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE; TUMOR CELL LINE;

AMINOPYRIDINES; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; CRK-ASSOCIATED SUBSTRATE PROTEIN; FEMALE; FOCAL ADHESION PROTEIN-TYROSINE KINASES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SPHEROIDS, CELLULAR; SRC-FAMILY KINASES; TUMOR CELLS, CULTURED; TYROSINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77953709612     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.9.10.11434     Document Type: Article

References (49)

1. Schlaepfer DD, Hauck CR, Sieg DJ. Signaling through focal adhesion kinase. Prog Biophys Mol Biol 1999; 71:4-6.
2. Mitra SK, Hanson DA, Schlaepfer DD. Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol 2005; 6:56-68.
3. Tomar A, Schlaepfer DD. Focal adhesion kinase: switching between GAPs and GEFs in the regulation of cell motility. Curr Opin Cell Biol 2009; 21:676-83.
4. McLean GW, Carragher NO, Avizienyte E, Evans J, Brunton VG, Frame MC. The role of focal-adhesion kinase in cancer - a new therapeutic opportunity. Nat Rev Cancer 2005; 5:505-15.
5. Zhao J, Guan JL. Signal transduction by focal adhesion kinase in cancer. Cancer Metastasis Rev 2009; 28:35-49.
6. Parsons JT, Slack-Davis J, Tilghman R, Roberts WG. Focal adhesion kinase: targeting adhesion signaling pathways for therapeutic intervention. Clin Cancer Res 2008; 14:627-32.
7. Benlimame N, He Q, Jie S, Xiao D, Xu YJ, Loignon M, et al. FAK signaling is critical for ErbB-2/ErbB-3 receptor cooperation for oncogenic transformation and invasion. J Cell Biol 2005; 171:505-16.
8. Luo M, Fan H, Nagy T, Wei H, Wang C, Liu S, et al. Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem/progenitor cells. Cancer Res 2009; 69:466-74.
9. Provenzano PP, Inman DR, Eliceiri KW, Beggs HE, Keely PJ. Mammary epithelial-specific disruption of focal adhesion kinase retards tumor formation and metastasis in a transgenic mouse model of human breast cancer. Am J Pathol 2008; 173:1551-65.
10. Lahlou H, Sanguin-Gendreau V, Zuo D, Cardiff RD, McLean GW, Frame MC, et al. Mammary epithelial-specific disruption of the focal adhesion kinase blocks mammary tumor progression. Proc Natl Acad Sci USA 2007; 104:20302-7.
11. Pylayeva Y, Gillen KM, Gerald W, Beggs HE, Reichardt LF, Giancotti FG. Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling. J Clin Invest 2009; 119:252-66.
12. van Nimwegen MJ, Verkoeijen S, van Buren L, Burg D, van de Water B. Requirement for focal adhesion kinase in the early phase of mammary adenocarcinoma lung metastasis formation. Cancer Res 2005; 65:4698-706.
13. Mitra SK, Lim ST, Chi A, Schlaepfer DD. Intrinsic focal adhesion kinase activity controls orthotopic breast carcinoma metastasis via the regulation of urokinase plasminogen activator expression in a syngeneic tumor model. Oncogene 2006; 25:4429-40.
14. Mitra SK, Schlaepfer DD. Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol 2006; 18:516-23.
15. Shi Q, Hjelmeland AB, Keir ST, Song L, Wickman S, Jackson D, et al. A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth. Mol Carcinog 2007; 46:488-96.
16. Slack-Davis JK, Martin KH, Tilghman RW, Iwanicki M, Ung EJ, Autry C, et al. Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem 2007; 282:14845-52.
17. Roberts WG, Ung E, Whalen P, Cooper B, Hulford C, Autry C, et al. Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. Cancer Res 2008; 68:1935-44.
18. Golubovskaya VM, Nyberg C, Zheng M, Kweh F, Magis A, Ostrov D, et al. A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the y397 site of focal adhesion kinase decreases tumor growth. J Med Chem 2008; 51:7405-16.
19. Liu TJ, LaFortune T, Honda T, Ohmori O, Hatakeyama S, Meyer T, et al. Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo. Mol Cancer Ther 2007; 6:1357-67.
20. Halder J, Lin YG, Merritt WM, Spannuth WA, Nick AM, Honda T, et al. Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res 2007; 67:10976-83.
21. Golubovskaya VM, Virnig C, Cance WG. TAE226-Induced apoptosis in breast cancer cells with overexpressed Src or EGFR. Mol Carcinog 2007; 47:222-34.
22. Hochwald SN, Nyberg C, Zheng M, Zheng D, Wood C, Massoll NA, et al. A novel small molecule inhibitor of FAK decreases growth of human pancreatic cancer. Cell Cycle 2009; 8:2435-43.
23. Lim S-T, Mikolon D, Stupack DG, Schlaepfer DD. FERM control of FAK function: Implications for cancer therapy. Cell Cycle 2008; 7:2306-14.
24. Weis SM, Lim ST, Lutu-Fuga KM, Barnes LA, Chen XL, Göthert JR, et al. Compensatory role for Pyk2 during angiogenesis in adult mice lacking endothelial cell FAK. J Cell Biol 2008; 181:43-50.
25. Zouq NK, Keeble JA, Lindsay J, Valentijn AJ, Zhang L, Mills D, et al. FAK engages multiple pathways to maintain survival of fibroblasts and epithelia: differential roles for paxillin and p130Cas. J Cell Sci 2009; 122:357-67.
26. Wu L, Bernard-Trifilo JA, Lim Y, Lim ST, Mitra SK, Uryu S, et al. Distinct FAK-Src activation events promote alpha5beta1 and alpha4beta1 integrin-stimulated neuroblastoma cell motility. Oncogene 2008; 27:1439-48.
27. Defilippi P, Di Stefano P, Cabodi S. p130Cas: a versatile scaffold in signaling networks. Trends Cell Biol 2006; 16:257-63.
28. Sieg DJ, Hauck CR, Ilic D, Klingbeil CK, Schaefer E, Damsky CH, et al. FAK integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol 2000; 2:249-56.
29. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991; 139:271-9.
30. Mazumder S, Plesca D, Almasan A. Caspase-3 activation is a critical determinant of genotoxic stress-induced apoptosis. Methods Mol Biol 2008; 414:13-21.
31. Friedrich J, Seidel C, Ebner R, Kunz-Schughart LA. Spheroid-based drug screen: considerations and practical approach. Nat Protoc 2009; 4:309-24.
32. Almeida EA, Ilic D, Han Q, Hauck CR, Jin F, Kawakatsu H, et al. Matrix survival signaling: from fibronectin via focal adhesion kinase to c-Jun NH(2)-terminal kinase. J Cell Biol 2000; 149:741-54.
33. Shield K, Ackland ML, Ahmed N, Rice GE. Multicellular spheroids in ovarian cancer metastases: Biology and pathology. Gynecol Oncol 2009; 113:143-8.
34. Frisch SM, Vuori K, Ruoslahti E, Chan-Hui PY. Control of adhesion-dependent cell survival by focal adhesion kinase. J Cell Biol 1996; 134:793-9. (Pubitemid 26269148)
35. Hungerford JE, Compton MT, Matter ML, Hoffstrom BG, Otey CA. Inhibition of pp125FAK in cultured fibroblasts results in apoptosis. J Cell Biol 1996; 135:1383-90.
36. Stupack DG, Cheresh DA. Get a ligand, get a life: integrins, signaling and cell survival. J Cell Sci 2002; 115:3729-38.
37. Lim ST, Miller NL, Nam JO, Chen XL, Lim Y, Schlaepfer DD. PYK2 inhibition of p53 as an adaptive and intrinsic mechanism facilitating cell proliferation and survival. J Biol Chem 2009; 285:1743-53.
38. Ilic D, Almeida EA, Schlaepfer DD, Dazin P, Aizawa S, Damsky CH. Extracellular matrix survival signals transduced by focal adhesion kinase suppress p53-mediated apoptosis. J Cell Biol 1998; 143:547-60.
39. Sawada Y, Tamada M, Dubin-Thaler BJ, Cherniavskaya O, Sakai R, Tanaka S, et al. Force sensing by mechanical extension of the Src family kinase substrate p130Cas. Cell 2006; 127:1015-26.
40. Cho SY, Klemke RL. Extracellular-regulated kinase activation and CAS/Crk coupling regulate cell migration and suppress apoptosis during invasion of the extracellular matrix. J Cell Biol 2000; 149:223-36.
41. Cabodi S, Tinnirello A, Di Stefano P, Bisaro B, Ambrosino E, Castellano I, et al. p130Cas as a new regulator of mammary epithelial cell proliferation, survival and HER2-neu oncogene-dependent breast tumorigenesis. Cancer Res 2006; 66:4672-80.
42. Provenzano PP, Keely PJ. The role of focal adhesion kinase in tumor initiation and progression. Cell Adh Migr 2009; 3:347-50.
43. Michael KE, Dumbauld DW, Burns KL, Hanks SK, Garcia AJ. FAK Modulates Cell Adhesion Strengthening via Integrin Activation. Mol Biol Cell 2009; 20:2508-19.
44. Frisch SM. Caspase-8: fly or die. Cancer Res 2008; 68:4491-3.
45. Walsh C, Tanjoni I, Uryu S, Nam JO, Mielgo A, Tomar A, et al. Oral delivery of PND-1186 FAK inhibitor decreases spontaneous breast to lung metastasis in preclinical tumor models. Cancer Biol Ther 2010; 9.
46. Wu YM, Tang J, Zhao P, Chen ZN, Jiang JL. Morphological changes and molecular expressions of hepatocellular carcinoma cells in three-dimensional culture model. Exp Mol Pathol 2009; 87:133-40.
47. Liang C, Koenig M, He Y, Holmberg P. Inhibitors of Focal Adhesion Kinase. World Intellectual Property Organization 2008; WO2008115369.
48. Roby KF, Taylor CC, Sweetwood JP, Cheng Y, Pace JL, Tawfik O, et al. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis 2000; 21:585-91. (Pubitemid 30214011)
49. Lim Y, Lim ST, Tomar A, Gardel M, Bernard-Trifilo JA, Chen XL, et al. PyK2 and FAK connections to p190Rho guanine nucleotide exchange factor regulate RhoA activity, focal adhesion formation and cell motility. J Cell Biol 2008; 180:187-203.